SCHEMBL4825573

SCHEMBL4825573

COc1ccc(C(=O)Oc2cc(OCCO/N=C/c3ccc(C(C)(C)C)cc3)ccc2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
KMT2A Q03164 4/20 0.41
GFER P55789 1/20 0.41
ALDH1A1 P00352 5/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
PTPN1 P18031 2/20 0.39
MEN1 O00255 3/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 5/20 0.38
RECQL P46063 3/20 0.38
ALOX15 P16050 1/20 0.38
APEX1 P27695 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4825579 1.00 MAPT (0.41) MAPTKMT2AGFERALDH1A1CA1
SCHEMBL4825687 0.96 ALDH1A1 (0.42) MAPTKMT2AGFERALDH1A1CA1
SCHEMBL4825682 0.96 ALDH1A1 (0.42) MAPTKMT2AGFERALDH1A1CA1
SCHEMBL4830776 0.92 ALDH1A1 (0.41) ALDH1A1CA1CA2LMNARECQL
SCHEMBL4830783 0.92 ALDH1A1 (0.41) ALDH1A1CA1CA2LMNARECQL
SCHEMBL4828924 0.92 MAPT (0.44) MAPTKMT2AALDH1A1CA1CA2
SCHEMBL4828934 0.92 MAPT (0.44) MAPTKMT2AALDH1A1CA1CA2
SCHEMBL4826234 0.91 MAPT (0.42) MAPTKMT2AGFERALDH1A1CA1
SCHEMBL4826227 0.91 MAPT (0.42) MAPTKMT2AGFERALDH1A1CA1
SCHEMBL4829025 0.87 ALDH1A1 (0.43) MAPTKMT2AALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 MAPT 4769/4885KMT2A 416/4885GFER 226/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 MAPT 4362/4885KMT2A 757/4885GFER 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.